Deutsche Sanierungsberatung (dsb) provides a digital platform for planning and executing energy-efficient residential renovations, including insulation and solar panel installations.

Perceive Pharma develops novel small molecule neuroprotective therapeutics for ophthalmic diseases, including glaucoma.

TECLens develops a non-invasive ophthalmic device that uses corneal cross-linking technology to reshape the cornea for vision correction.

EDGLRD is a digital IP-based studio that collaborates with prominent artists and brands to create and distribute innovative content using proprietary AI-based technology.

Alessa Therapeutics develops localized drug delivery systems for early cancer treatment, focusing on minimizing systemic side effects.

Cala Health develops non-invasive, FDA-cleared wearable devices for hand tremor relief, focusing on essential tremor and Parkinson's disease.

Citryll is a biotech company developing therapies for immune-mediated inflammatory diseases, focusing on a monoclonal antibody targeting Neutrophil Extracellular Traps (NETs).

TRexBio is a biotechnology company developing novel therapies for inflammatory diseases using their Deep Biology platform to focus on immune homeostasis.

Orasis Pharmaceuticals develops and commercializes corrective eye drops for treating presbyopia in adults.

SpectraWAVE, Inc. develops advanced medical imaging systems to improve coronary stenting procedures and enhance clinical decision-making in the treatment of coronary artery disease.

HistoSonics is a medical device company that develops non-invasive histotripsy platforms, including the Edison® Histotripsy System, to mechanically destroy and liquefy targeted liver tumors using focused ultrasound.

Aro Biotherapeutics is a clinical stage biotech company specializing in the development of tissue-targeted genetic medicines, including a potential treatment for Pompe Disease and new therapies for autoimmune disorders, using their proprietary Centyrin-siRNA platform.

On Target Laboratories develops and commercializes FDA-approved imaging agents for cancer surgeries, using near-infrared dye and targeting molecules to aid in detecting and resecting cancer cells.

RefleXion Medical develops and commercializes SCINTIX therapy, a novel treatment for all stages of indicated solid tumor cancers, including metastatic disease, delivered via the RefleXion X1 platform.

Osteal Therapeutics is a clinical-stage biopharmaceutical company that develops novel musculoskeletal therapeutics to treat orthopedic infections, with its lead therapy, VT-X7, currently in Phase 2 development for chronic periprosthetic joint infections.

Arialys Therapeutics is a biotechnology company that develops precision medicines to target pathogenic autoantibodies in the central nervous system, with a focus on treating neuropsychiatric diseases caused by autoimmunity.

ROME Therapeutics is a biotechnology company that develops breakthrough medicines for serious diseases, with a focus on an inhibitor of LINE-1 reverse transcriptase for autoimmune diseases, using their proprietary data science platform to identify active repeat elements and assess their roles in disease.

Rapport Therapeutics is a clinical-stage biotechnology company that develops precision neuromedicines for seizure and psychiatric disorders by targeting specific neuroanatomical regions, aiming to provide better alternatives to current treatments by reducing unwanted drug-target interactions.